Tk. Crilley et al., VASORELAXANT EFFECTS OF SCA40 (A PHOSPHODIESTERASE-III INHIBITOR) IN PULMONARY VASCULAR PREPARATIONS IN RATS, Clinical and experimental pharmacology and physiology, 25(5), 1998, pp. 355-360
1. The novel phosphodiesterase (PDE) inhibitor SCA40 methylamino)imida
zo[1,2-a]pyrazine-2-carbonitrile) was examined for its vasorelaxant ac
tivity on isolated pulmonary vascular preparations from rats, 2. SCA40
relaxed ring preparations of main and intralobar pulmonary artery pre
contracted submaximally with either phenylephrine or U46619 (thromboxa
ne-mimetic). Based on negative log EC50 values, SCA40 was six-to 14-fo
ld more potent than the PDE III inhibitor milrinone or the non-selecti
ve PDE inhibitor 3-isobutyl-1-methyl xanthine (IBMX). The potency of S
CA40 corresponded to its reported potency as a PDE III inhibitor. 3. I
n isolated perfused lungs, SCA40 reversed the vasoconstriction induced
by alveolar hypoxia, It was 49-fold more potent than IBMX, 4. In main
pulmonary artery the vasorelaxation induced by SCA40 was not blocked
by the large-conductance calcium-activated potassium channel (BKCa) in
hibitors iberiotoxin (50 and 100 nmol/L) or charybdotoxin (100 and 300
nmol/L). This was in contrast to data on guinea-pig trachea, where re
sponses to SCA40 were significantly inhibited by charybdotoxin (100 nm
ol/L). 5. It is concluded that opening of BKCa channels does not contr
ibute to the pulmonary vasorelaxant effects of SCA40 in main pulmonary
artery and it is likely that responses reflect the PDE III inhibitory
properties of the drug. 6. It is postulated that SCA40 may be useful
as a pulmonary vasodilator in disorders such as pulmonary hypertension
.